Large-scale Production & Purification Of Compounds With

大规模生产

• 批准号: 6503224
• 负责人: Joseph Shiloach
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6503224
• 关键词: Clostridium; Escherichia coli; HeLa cells; Salmonella typhi; Shigella vaccines; bacterial proteins; biological products; biotechnology; chemical registry /resource; diphtheria toxin; fermentation; glucose metabolism; immunological substance; method development; microarray technology; microorganism mass culture; microorganism resource /registry; protein purification; recombinant DNA; recombinant proteins; tissue /cell culture; vaccine development; vaccinia virus

The Biotechnology Unit is responsible for the production and purification of biological material. The Unit undertakes a wide array of biological production tasks such as large-scale growth of prokaryotes and eucaryotes, and production and purification of biological compounds especially proteins. These products, not available from commercial sources, are needed for clinical and structural studies. The Biotechnology Unit is capable of handling these various production tasks by implementing both physiological and technical approaches. Efficient process development and production is possible since the Unit possesses two integrated elements: a fully operational multi-purpose pilot production facility and the capability of conducting research and process development. During the last year the unit performed approximately 200 different, large scale preparations including: 1) growing various microorganisms such as recombinant Escherichia coli, recombinant Saccharomyces cerevisiae, recombinant Pichia pastoris, mutant strains of Corynebacteria diphtheria, several types of Salmonella and Shigella and mutant strain of Bacillus anthracis; 2) propagating large volumes of various eucaryotic cells such as HeLa, CHO, drosophila and Sf-9; 3) purifying gram quantities of diphtheria toxin CRM (Cross Reacting Material) and recombinant Pseudomonas aeruginosa exotoxin A needed for the preparation of conjugated vaccines. In the research and development arena, the unit continues its work in the following topics: 1) development of more efficient methods for large scale protein recovery, here we performed experiments implementing expanded bed adsorption techniques for capturing proteins on ion exchangers, chelating and hydrophobic resins; 2) conducting research aimed at understanding the glucose metabolism of various recombinant E. coli strains in an effort to find out why certain strains are more suitable for foreign protein production using microarrays technology and protein analysis; 3) developing fermentation procedures for expressing sensitive, recombinant clostridium protein from e.coli by suppressing proteolytic activity; and 4) conducting experiments for improving the production protocol of recombinant proteins from Pichia pastoris, especially endostatin. In addition, the unit continues its research work in two topics, one is on the effect of various high density growth strategies of recombinant E.coli, on the production of recombinant proteins, and the other is on the production process of recombinant proteins from the HeLa/vaccinia system. In collaboration with LDMI, NICHD, the unit conducted work on the development of new vaccine against Salmonella typhi, and shigella flexneri. The products are currently in field trials.

生物技术股负责生物材料的生产和纯化。该股承担广泛的生物生产任务，如大规模生长原核生物和真核生物，以及生产和纯化生物化合物，特别是蛋白质。这些产品不能从商业来源获得，但需要用于临床和结构研究。生物技术股能够通过实施生理和技术方法来处理这些不同的生产任务。有效的工艺发展和生产是可能的，因为该股拥有两个综合要素：一个充分运作的多用途试验生产设施和进行研究和工艺发展的能力。去年，该单位进行了大约200种不同的大规模制备，包括：1)培养各种微生物，如重组大肠杆菌、重组酿酒酵母、重组毕赤酵母、白喉链杆菌突变株、几种沙门氏菌和志贺氏菌以及炭疽芽孢杆菌突变株；2)大量繁殖各种真核细胞，如HeLa、CHO、果蝇、Sf-9等；3)纯化制备结合疫苗所需的白喉毒素CRM （Cross reaction Material）和重组铜绿假单胞菌外毒素A的克量。在研究和开发领域，该部门继续开展以下主题的工作：1)开发更有效的大规模蛋白质回收方法，在这里我们进行了实验，实现了扩展床吸附技术，用于捕获离子交换器，螯合和疏水树脂上的蛋白质；2)开展旨在了解各种重组大肠杆菌菌株葡萄糖代谢的研究，利用微阵列技术和蛋白质分析找出为什么某些菌株更适合外源蛋白生产；3)通过抑制蛋白水解活性，开发从大肠杆菌中表达敏感、重组梭状芽胞杆菌蛋白的发酵工艺；4)对毕赤酵母重组蛋白特别是内皮抑素的生产工艺进行改进实验。此外，该单位还继续开展了两个课题的研究工作，一是关于重组大肠杆菌的各种高密度生长策略对重组蛋白生产的影响，另一个是关于HeLa/牛痘系统重组蛋白的生产过程。该股与LDMI、NICHD合作，开展了针对伤寒沙门氏菌和福氏志贺氏菌的新疫苗开发工作。这些产品目前正在进行现场试验。